CD4 T-cells reprogrammed to kill cancer — a Nordic innovation in IT and immunology
Catavax develops the world's first immunotherapy that makes CD4 T cells toxic enough to kill cancer — a biological gamechanger based on IT and immunology.
CD8 focus, immune evasion, poor personalization
CD4 cytotoxic activation + bioinformatic targeting
PartnersLast week we had a visit from MD Anderson Cancer Center (MDACC, Houston, USA) by Dr. Samir Hanash to discuss research collaboration. From left: Camilla Petrycer Hansen (Novo Holdings), Morten Nielsen (DTU), Caspar Skovbo Christensen and Kaare Nørgaard (Catavax), Samir Hanash (MDACC), and Allan Rasmussen (Rigshospitalet).
NewsCatavax has received an Innobooster grant from Innovationsfonden within breast cancer vaccine development. It is evidence that Catavax is onto something that has potential, and it will enable more innovation within cancer vaccine development in Catavax.
PartnersPartnership agreement: We have entered into a partnership with UTMB (University of Texas Medical Branch), which is located in Galveston, Texas. The partnership agreement covers the development of Cancer Vaccines together as well as investigating whether the Catavax method can be utilized in other vaccines.
StaffTEAM NEWS: In order to intensify our quest to curing cancer, we have expanded our staff with Thomas Simonsen
PartnersWe traveled to Houston and have made a partnership with MD Anderson, the best cancer hospital (in the USA) and the largest in the world.
EventWe hosted a visit of the Minister of Economics, Stephanie Lose, and the Frederiksberg Mayor candidate, Jan E. Jørgensen. They were here in Symbion to hear about the main source of value creation in Denmark (potentially "the next Novo") and the future cure for cancer.
StaffTEAM NEWS: After a successful preclinical test, which brings us one step closer to curing cancer, we have expanded our staff with Linh Trinh and Caspar Skovbo Christensen
LabWe have finished the first pre-clinical trials with interesting data from the lab (human blood samples and our test vaccine). Now it is time to start animal trials. One step closer to curing (some major) cancers.
LabWe have just started our pre-clinical tests, that will show if the immune system has a response that under special conditions that we create will kill the cancer. To the right is Linh (in charge of the trial), to the left is Caroline.
LabCuring cancer (?) Soon we will start pre-clinical testing to see if we are right in our assumption on how the immune system functions - so that we can harness it to kill cancer. In the picture are (from left to right): Linh (who is responsible for the tests carried out by Hervolution), Kaare (CEO of Catavax), Peter (Founder of Hervolution), and Christian (chairman of Catavax)
EventWe have founded Catavax A/S in DK and US. Capital raised, patent applications submitted, pre-clinical trials started. We wish to find one or a significant part of a cure for cancer, utilizing the immune system.
Secure, exclusive access.
Access confidential updates, milestones, and investor materials. Stay informed on our progress in next-generation cancer immunotherapy.
